ReviewTherapeutic advances in psychopharmacology2021
Cognitive effects of vortioxetine in older adults: a systematic review.
Review in Therapeutic advances in psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Use of vortioxetine in different neurological fields: a systematic review and future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Cognitive Impairment, Dementia and Depression in Older Adults.Journal of clinical medicine · 2026Review
- Vortioxetine in Subgroups of Patients with Major Depressive Disorder and Early-Stage Dementia: Further Results from the MEMORY Study.Neuropsychiatric disease and treatment · 2026Article
- Evaluating the rational use of antidepressant in older patients: a comprehensive analysis of its association with cognitive impairment.Frontiers in psychiatry · 2025Article
- Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment.Frontiers in psychiatry · 2025Article
- Association between social engagement decline and cognitive function changes: mediating effect of depressive symptoms.Aging clinical and experimental research · 2024Article
- Exploring the Complex Relationship Between Antidepressants, Depression and Neurocognitive Disorders.Biomedicines · 2024Review
- Effectiveness of Vortioxetine Treatment on Depression and Cognitive Functions in Patients with Alzheimer's Disease: A 12-Month, Retrospective, Observational Study.Journal of personalized medicine · 2024Article
- Treating Depression in Dementia Patients: A Risk or Remedy-A Narrative Review.Geriatrics (Basel, Switzerland) · 2024Review
- Article
- The efficacy of vortioxetine for the delusional disorder of cenesthopathy.Neuropsychopharmacology reports · 2024Article
- Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023.Molecules (Basel, Switzerland) · 2023Review
- Exploring depression in Alzheimer's disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Association between Antidepressants and Dementia Risk in Older Adults with Depression: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Exploring depression in Parkinson's disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Catecholaminergic and Cholinergic Systems Mediate Beneficial Effect of Vortioxetine on Diabetes-Induced Neuropathic Pain.Biomedicines · 2023Article
- Listening to your partner: serotonin increases male responsiveness to female vocal signals in mice.Frontiers in human neuroscience · 2023Article
- Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.Frontiers in aging neuroscience · 2022Article
- Vortioxetine as adjunctive therapy in the treatment of schizophrenia.Therapeutic advances in psychopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many older adults experience a deterioration in cognitive function with aging, and this can have a negative impact on quality of life. Late-life depression has been linked to mild cognitive impairment and dementia, and treating depression with an agent that has procognitive effects could be beneficial. Vortioxetine is a novel antidepressant with a multimodal mechanism of action that works primarily
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.